174 related articles for article (PubMed ID: 20858024)
1. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Breccia M; Alimena G
Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.
Bruserud Ø; Reikvam H
Expert Opin Ther Targets; 2010 Nov; 14(11):1139-42. PubMed ID: 20942744
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies.
Panwalkar A; Verstovsek S; Giles F
Cancer; 2004 Apr; 100(8):1578-89. PubMed ID: 15073843
[TBL] [Abstract][Full Text] [Related]
4. Targeting NF-kappaB in hematologic malignancies.
Braun T; Carvalho G; Fabre C; Grosjean J; Fenaux P; Kroemer G
Cell Death Differ; 2006 May; 13(5):748-58. PubMed ID: 16498458
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Fabre C; Carvalho G; Tasdemir E; Braun T; Adès L; Grosjean J; Boehrer S; Métivier D; Souquère S; Pierron G; Fenaux P; Kroemer G
Oncogene; 2007 Jun; 26(28):4071-83. PubMed ID: 17213804
[TBL] [Abstract][Full Text] [Related]
6. NF-kappaB and IKK as therapeutic targets in cancer.
Kim HJ; Hawke N; Baldwin AS
Cell Death Differ; 2006 May; 13(5):738-47. PubMed ID: 16485028
[TBL] [Abstract][Full Text] [Related]
7. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation.
Viatour P; Merville MP; Bours V; Chariot A
Trends Biochem Sci; 2005 Jan; 30(1):43-52. PubMed ID: 15653325
[TBL] [Abstract][Full Text] [Related]
9. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
10. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
11. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
12. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
13. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
Jenkins C; Hewamana S; Gilkes A; Neelakantan S; Crooks P; Mills K; Pepper C; Burnett A
Br J Haematol; 2008 Dec; 143(5):661-71. PubMed ID: 19036014
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Carvalho G; Fabre C; Braun T; Grosjean J; Ades L; Agou F; Tasdemir E; Boehrer S; Israel A; Véron M; Fenaux P; Kroemer G
Oncogene; 2007 Apr; 26(16):2299-307. PubMed ID: 17043643
[TBL] [Abstract][Full Text] [Related]
17. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.
Fuchs O
Curr Mol Pharmacol; 2010 Nov; 3(3):98-122. PubMed ID: 20594187
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
Ciucci A; Gianferretti P; Piva R; Guyot T; Snape TJ; Roberts SM; Santoro MG
Mol Pharmacol; 2006 Nov; 70(5):1812-21. PubMed ID: 16908599
[TBL] [Abstract][Full Text] [Related]
19. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring and synthetic inhibitors of NF-kappaB functions.
Umezawa K; Ariga A; Matsumoto N
Anticancer Drug Des; 2000 Aug; 15(4):239-44. PubMed ID: 11200499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
